CVS Health (NYSE:CVS) is expanding access to GLP-1 weight-loss drugs, including reintroducing Zepbound and adding new oral therapy Foundayo, through updated formularies. Aetna is rolling out “Aetna Mental Health On Demand,” offering real-time access to clinicians and new AI tools for documentation support and care management. The company is pairing these moves with broader community health initiatives and greater use of AI across its health services.
For investors watching NYSE:CVS, these product and service launches come as the stock trades around $90.98, with a return of 13.5% year to date and 47.3% over the past year. The moves are part of CVS Health’s broader push to combine pharmacy, insurance, and care delivery into a single, integrated platform.
The broadened GLP-1 access and new mental health offering highlight areas where CVS Health appears focused on member engagement, cost management, and digital tools. These developments provide more concrete touchpoints to monitor how the company executes on high-profile areas of care, especially weight management and behavioral health.
Stay updated on the most important news stories for CVS Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on CVS Health.
NYSE:CVS Earnings & Revenue Growth as at May 2026
We’ve flagged 5 risks for CVS Health. See which could impact your investment.
Quick Assessment ⚖️ Price vs Analyst Target: At US$90.98 versus a consensus target of US$102.08, CVS Health trades roughly 11% below the average analyst view. ✅ Simply Wall St Valuation: The stock is assessed as undervalued, trading about 69.9% below an estimated fair value based on discounted cash flows. ✅ Recent Momentum: A 10.8% return over the last 30 days shows positive short term momentum as these GLP-1 and mental health initiatives roll out.
There is only one way to know the right time to buy, sell or hold CVS Health. Head to Simply Wall St’s
company report for the latest analysis of CVS Health’s Fair Value.
Key Considerations 📊 Expanded GLP-1 access and new mental health services could influence how much of CVS Health’s US$405.6b revenue base comes from higher touch, service driven lines of business. 📊 Watch how AI supported care management and documentation tools show up in operating costs, member engagement metrics, and any commentary around GLP-1 utilization trends. ⚠️ With debt not well covered by operating cash flow and profit margins at 0.7% versus an industry average margin of 6.2%, balance sheet resilience is an important counterpoint to the growth initiatives. Dig Deeper
For the full picture including more risks and rewards, check out the
complete CVS Health analysis. Alternatively, you can visit the
community page for CVS Health to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com